The Impact of Clinical Trials in Patients with Multiple Myeloma and Lymphoma


About this study

The purpose of this study is to evaluate quality of life over time in patients with multiple myeloma or lymphoma enrolled in clinical trials compared with patients on standard therapy.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Age > 18 years
  • Newly diagnosed or relapsed lymphoma or multiple myeloma starting on new therapy on clinical trial or off clinical trial
  • Provide written informed consent
  • Ability to complete questionnaire(s) in English by themselves or with assistance

Exclusion Criteria

  • History of autologous bone marrow transplant in past three months
  • History of allogeneic bone marrow transplant
  • Undergoing active chemotherapy for any other cancer concomitantly
  • Patients on single agent anti-CD20 antibodies alone
  • ECOG performance status 3 or worse
  • ANC < 1000
  • Inadequate organ function (bilirubin > 2x UNL, GFR < 30 ml/min; decompensated congestive heart failure)


Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Shaji Kumar, M.D.

Closed for enrollment

Contact information:

Surbhi Sidana M.B.B.S.

More information


Publications are currently not available

Mayo Clinic Footer